Evidence map›Paper›PMID 41193921›Full record

Observational studyClinical oral investigations2025

Effect of ruxolitinib on the oral mucosa in steroid-refractory graft-versus-host disease: a prospective observational exploratory study.

Mar Bellido, Ana-Mae E Jonk, Martina Kaurinovic, Anouschka Biswana, Carin L E Hazenberg, Goda Choi, Linde M Morsink, Gerwin Huls, Arjan Vissink, Konstantina Delli

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mar BellidoDepartment of Hematology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713 GZ, the Netherlands.ORCID 0000-0001-9864-5816
Ana-Mae E JonkDepartment of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713 GZ, the Netherlands.ORCID 0000-0001-7144-4192
Martina KaurinovicDepartment of Hematology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713 GZ, the Netherlands.ORCID 0000-0001-6424-2955
Anouschka BiswanaDepartment of Hematology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713 GZ, the Netherlands.
Carin L E HazenbergDepartment of Hematology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713 GZ, the Netherlands.ORCID 0000-0001-6973-4668
Goda ChoiDepartment of Hematology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713 GZ, the Netherlands.ORCID 0000-0003-2348-5947
Linde M MorsinkDepartment of Hematology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713 GZ, the Netherlands.ORCID 0000-0001-5408-5298
Gerwin HulsDepartment of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713 GZ, the Netherlands.ORCID 0009-0001-6789-6433
Arjan VissinkDepartment of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713 GZ, the Netherlands.ORCID 0000-0003-2581-4361
Konstantina DelliDepartment of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713 GZ, the Netherlands. k.delli@umcg.nl.ORCID 0000-0003-3115-3977

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo assess whether Steroid-Refractory chronic Graft-versus-Host Disease (SR-cGvHD) patients with oral involvement benefit from ruxolitinib regarding their clinical symptoms and oral lesions. MATERIALS AND

methodsA prospective real-life observational longitudinal patient study was conducted in patients with SR-cGVHD and oral involvement who were treated with ruxolitinib. The effects of ruxolitinib on oral lesions and symptoms were assessed 12 weeks after the start of treatment with ruxolitinib based on the complete response, partial response, and overall response rate. Additionally, oral mucosal clinical characteristics and symptoms were assessed using validated outcome scales 4 and 12 weeks after treatment.

resultsA total of 17 patients was included. Overall response rate after 12 weeks was 77%: 12% had a complete response and 65% had a partial response. A significant decrease was seen in presence of erythema (p = 0.002), lichenoid lesions (p = 0.001), median lesion site score (p = 0.001) and activity score (p = 0.001) after 12 weeks. Discomfort experienced by the patients in terms of mouth dryness, mouth pain, and mouth sensitivity was significantly ameliorated (p = 0.01).

conclusionTreatment of oral SR-cGVHD with ruxolitinib ameliorates oral lesions and symptoms experienced by patients. CLINICAL RELEVANCE: Ruxolitinib effectively treats symptoms of oral cGHVD as shown by real world evidence.

Indexed as

Graft vs Host DiseaseMouth DiseasesMouth MucosaPyrazolesAdultFemaleHumansLongitudinal StudiesMaleMiddle AgedNitrilesProspective StudiesPyrimidinesTreatment OutcomeNitrilesPyrazolesPyrimidinesruxolitinibLichen planusOral manifestationsOral mucosaOral SR-cGVHDRuxolitinib

Identifiers

PMID41193921
PMCPMC12589367

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.